ADVM•benzinga•
Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 14, 2022 by benzinga